Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.64 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.64 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.64 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30641927 | 1.00 | KMT2A (0.66) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL8930598 | 0.87 | MAPT (0.63) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL26727168 | 0.85 | KMT2A (0.71) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL1815770 | 0.84 | PKM (0.65) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL7130662 | 0.84 | RORC (0.73) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL27910937 | 0.84 | KMT2A (0.63) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL4969610 | 0.83 | PDK1 (0.76) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL4326710 | 0.82 | SMN1; SMN2 (0.58) | KMT2AALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL427418 | 0.82 | HTT (0.67) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL915213 | 0.82 | MEN1 (0.64) | KMT2AMEN1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240343681-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | DUKE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| EP-4313939-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | Corteva Agriscience LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117098750-A | Molecules having pesticidal utility, and intermediates and methods related thereto | 科迪华农业科技有限责任公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022204080-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204080-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3894392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Duke University (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-0250099-B1 | ORGANIC NONLINEAR OPTICAL MATERIAL | TORAY INDUSTRIES, INC. (JP) | 1993-01-27 | — | — | EP | disclosed |
| EP-0517871-A1 | NOVEL NITROANILIDES AND THEIR PREPARATION. | KODAK LTD (GB) | 1992-12-16 | — | — | EP | disclosed |
| US-5169986-A | Benzylidene-aniline derivative; laser resistance, durability | TORAY INDUSTRIES, INC. (JP) | 1992-12-08 | — | — | US | disclosed |
| WO-1992011230-A1 | NOVEL NITROANILIDES AND THEIR PREPARATION | KODAK LIMITED (GB) | 1992-07-09 | — | — | WO | disclosed |
| EP-0286021-B1 | REACTIVE AZO DYES | BASF Aktiengesellschaft (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4987255-A | EXCELLENT RESISTANCE TO LASER DAMAGE | TORAY INDUSTRIES, INC. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4897469-A | Aniline series azo reactive dyes ortho- or para-substituted by vinyl sulfonyl reactive groups | BASF AKTIENGESELLSCHAFT (DE) | 1990-01-30 | — | — | US | disclosed |
| EP-0286021-A2 | Reactive azo dyes | BASF Aktiengesellschaft (DE) | 1988-10-12 | — | — | EP | disclosed |
| EP-0250099-A2 | Organic nonlinear optical material | TORAY INDUSTRIES, INC. (JP) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | KMT2A 3139/4885MEN1 4220/4885PDK1 258/4885 |
| US-20240343681-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | KMT2A 2552/4885MEN1 1415/4885PDK1 237/4885 |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | HSF1, HSP90AB1, HSP90AA1 | KMT2A 3139/4885MEN1 4220/4885PDK1 258/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | KMT2A 3139/4885MEN1 4220/4885PDK1 258/4885 |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | KMT2A 3139/4885MEN1 4220/4885PDK1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.